E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Lymphocytic Leukaemia |
Chronická lymfocytární leukemie |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic lymphocytic leukemia is a cancer of the B-cels (a type of blood cell) |
Chronická lymfocytární leukemie je nádorové onemocnění vycházející z B- buněk (typ krevních buněk) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to evaluate progression free survival (PFS) of ofatumumab maintenance treatment
versus no further treatment after remission induction in subjects with relapsed Chronic Lymphocytic Leukaemia |
|
E.2.2 | Secondary objectives of the trial |
• Secondary objectives are to evaluate clinical benefit, safety, tolerability and health-related quality of life of
subjects treated with ofatumumab versus no further treatment. An additional secondary objective is to evaluate
the pharmacokinetics in CLL subjects on maintenance ofatumumab |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Adults with documented diagnosis of CLL based on the modified IWCLL updated NCI-WG guidelines
[Hallek, 2008]
2. At least PR according to the revised 2008 NCI-WG CLL criteria, within 3 months of the response assessment
after the last dose of 2nd/3rd line treatment
3. The anti-leukemic treatment before study entry should have been at least 3 months or 3 cycles of
polychemotherapy (e.g. CVP), fludarabine-containing chemotherapy or immunochemotherapy
4. ECOG Performance Status of 0-2
5. Signed written informed consent prior to performing any study-specific procedures
French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a
beneficiary of a social security category.
E. |
|
E.4 | Principal exclusion criteria |
1. Known primary or secondary fludarabine-refractory subjects, defined as treatment failure (failure to achieve a
CR or PR) or disease progression within 6 months [Hallek, 2008]
2. Prior maintenance therapy
3. Known transformation of CLL (e.g. Richter’s transformation), prolymphocytic leukemia (PLL), or CNS
involvement of CLL
4. Active Autoimmune Hemolytic Anemia (AIHA) requiring treatment except if in the opinion of the investigator
it is thought not to affect the subject’s safety, the conduct of the study or the interpretation of the data
5. Previous autologous or allogeneic stem cell transplantation
6. Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment
such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and
active Hepatitis B or C
(Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg
but HBcAb positive (regardless of HBsAb status), a HBV DNA test will be performed and if positive the subject
will be excluded*.)
7. Other past or current malignancy (with the exception of basal cell carcinoma of the skin or in situ carcinoma
of the cervix or breast) unless the tumor was successfully treated with curative intent at least 2 years prior to trial
entry except if in the opinion of the investigator it is thought not to affect the subject’s safety, the conduct of the
study or the interpretation of the data
8. Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months
prior to screening, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles
or minor conduction abnormalities except if in the opinion of the investigator it is thought not to affect the
subject’s safety, the conduct of the study or the interpretation of the data
9. History of significant cerebrovascular disease or event with symptoms or sequelae
10. Significant concurrent, uncontrolled medical condition that in the opinion of the investigator contraindicates
participation in this study
11. Other anti-leukemic use of medications including glucocorticoids
12. Known HIV positive
13. Screening laboratory values:
• Platelets<50 x 10^9/L
• Neutrophils<1.0 x 10^9/L
• Creatinine > 1.5 times upper normal limit (unless normal creatinine clearance)
• Total bilirubin > 1.5 times upper normal limit (unless due to liver involvement of CLL)
• Alanine Aminotransferase (ALT) > 2.5 times upper normal limit (unless due to liver involvement of CLL or
Gilbert's syndrome)
• Alkaline phosphatase > 2.5 times upper normal limit
14. Known or suspected hypersensitivity to ofatumumab that in the opinion of the investigator or medical monitor
contraindicates study participation
15. Subjects who have received treatment with any non-marketed drug substance or experimental therapy
within 5-terminal half-lives or 4 weeks whichever is longer prior to first dose of study medication or currently
participating in any other interventional clinical study
Note: Participation in any other interventional clinical study after disease progression during post PD follow-up
is permitted.
16. Lactating women, women with a positive pregnancy test at Visit 1 or women (of childbearing potential) as
well as men with partners of childbearing potential, who are not willing to use adequate contraception from
study start through one year following last ofatumumab dose. Adequate contraception is defined as abstinence,
oral hormonal birth control, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive
patches, intrauterine device, and male partner sterilization if male partner is sole partner for that subject. For
females in the USA, the use of a double barrier method is also considered adequate (condom or occlusive cap
plus spermicidal agent).
* If HBV DNA is negative, subject may be included but must undergo HBV DNA monitoring (see Section 6.3.4).
Prophylactic antiviral therapy may be initiated at the discretion of the investigator. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is progression-free-survival (PFS) which is defined as the time from randomization to the
date of disease progression or death due to any cause. The investigator assessment of response will be assessed
according to the IWCLL updated NCI-WG CLL criteria [Hallek, 2008].
E.6 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 3 Cycles of ofatumumab plus bendamustine treatment. Last Subject = approx. Nov-2012
After 6 Cycles of ofatumumab plus bendamustine treatment. Last Subject = approx. Feb-2013
After the last dose, if not after 6 cycles, of ofatumumab plus bendamustine treatment. Last Subject = approx. Feb-2013
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
sledování |
observation only |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 98 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Czech Republic |
Germany |
Greece |
Italy |
Poland |
Russian Federation |
Spain |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |